Some more approval applications in Europe...
biz.yahoo.com
New Applications Target Lung and Esophageal Cancers
VANCOUVER, Jan. 6 /PRNewswire/ -- QLT PhotoTherapeutics Inc. (QLT) (Nasdaq: QLTIF - news; TSE: QLT. - news) announced today that in conjunction with its European marketing partner, Beaufour Ipsen Group, it has submitted applications in nine European Union (EU) countries, including the United Kingdom, for approval of its light-activated drug PHOTOFRIN(R) (porfimer sodium) as a treatment for certain lung and esophageal cancers.
The applications were filed in the UK, Ireland, Spain, Portugal, Belgium, Denmark, Sweden, Finland, and Greece.
... |
